Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up
BioCentury This Week
00:00
Aftua Lungibodysan
oll b m s thinks that it can sort of encroach in that market space that kitrudes has occupied. The idea is that they haven't seen that much monotherapy activity for relalama, which is the lag three anti bodied component of this fixed dose combination. It's more convenient for patients to have one infusion versus two.
Transcript
Play full episode
